Lumida
/MXCT
⌘K
MaxCyte Inc

MaxCyte Inc

MXCT
$1.24USD↓-8.15%-0.11 today

MARKET CAP

132.8M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$1 – $1

52W RANGE

$1
$2

AI Summary

Stalk
Buy NowMedium

MXCT remains in a Stage 2 advance, evidenced by higher highs and higher lows over the past quarter, but the active Blow-Off Top pattern signals a terminal phase and elevated transition risk. Price is currently pulling back into the rising 9/21 EMA zone, offering a favorable execution point, with short-term indicators in neutral territory and no clear exhaustion. Medium-term structure remains bullish as long as intermediate support holds, although the long-term downtrend suggests caution. Overall, conditions align for tactical participation on the long side now.

  • ↑$147.7 M cash and no debt provides strategic investment flexibility
  • ↑SPL program-related revenue up 62% YoY to $3.4 M on clinical milestones
  • ↓Q1 total revenue declined 7% YoY to $9.7 M, missing growth targets
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

MaxCyte, Inc. (NASDAQ: MXCT) is a pioneering company in the life sciences sector, specializing in cell and gene therapy solutions through its unique platform licenses (SPL). The company focuses on providing advanced technologies for researchers and therapeutic developers, particularly in the cell therapy and gene editing spaces. Despite recent challenges, MaxCyte is positioned for potential growth driven by strategic partnerships and an expanding product pipeline, which includes the integration of SecureDX.

Bull says

  • ↑$147.7 M cash and no debt provides strategic investment flexibility
  • ↑SPL program-related revenue up 62% YoY to $3.4 M on clinical milestones
  • ↑$10 M share buyback authorized, signaling management confidence
  • ↑Expert DTX launch and SecureDX integration could boost future revenues
  • ↑Favorable FDA gene-editing guidance may expand solution demand
  • ↑High book-to-price ratio and low volatility suggest value and stability

Bear says

  • ↓Q1 total revenue declined 7% YoY to $9.7 M, missing growth targets
  • ↓Core revenues slid 25% YoY to $6.2 M, straining operational performance
  • ↓Heavy reliance on SPL milestones adds revenue timing risk
  • ↓Negative profitability and weak earnings-yield metrics signal margin stress
  • ↓Elevated short interest reflects investor skepticism on recovery
  • ↓Intense competition from larger biotechs may limit new partnerships

Earnings Call · Q1 2025 · Mgmt. Guidance

Updated 05-31-2026bullish

Transcript signals

Bull points

  • total revenue was $10.4 million, which included strong core revenue of $8.2 million and SPL program-related revenue of $2.1 million.
  • We have begun 2025 as a more agile and focused company than ever before, which has allowed us to adapt to the dynamic macro backdrop so far this year.
  • The streamlining of the business resulted in some workforce changes, including a reduction in inefficiencies and the addition of key personnel. These changes across MaxSight have improved accountability and better aligned resources with the company's long-term goals.
Read full transcript analysis ›